01—Abstract
Summary
Summary of the 10-Q filed July 25, 2023. Cited figures are marked; the original filing is the authoritative source.
GE HealthCare Technologies Inc. reported solid top-line growth in its second quarter of 2023, with total revenues increasing by 7% year-over-year to $4.8 billiona, and 9% on an organic basis.
This growth was driven by strong performance across all segments, particularly Pharmaceutical Diagnostics (PDx) and Imaging. The company also saw continued improvements in supply chain fulfillment and benefits from price increases. Despite revenue growth, net income attributable to GE HealthCare decreased by 14% to $418 millionb, primarily impacted by higher interest expenses related to new debt issuances and the drawn Term Loan Facility, as well as increased operating expenses related to the company's transition to a standalone entity.
The company also highlighted ongoing investments in R&D and commercial initiatives. GE HealthCare maintained a strong balance sheet with $1.9 billionc in cash and cash equivalents and access to significant credit facilities, indicating financial stability. The company reiterated its full-year outlook, underscoring its confidence in continued growth and operational execution.
02—Key points
Key Highlights
- Total revenues increased 7% to $4.8 billion, with 9% organic growth, reflecting broad-based segment performance.
- Pharmaceutical Diagnostics (PDx) and Imaging segments showed particularly strong revenue growth, up 19% and 7% respectively.
- Net income attributable to GE HealthCare declined 14% to $418 million, impacted by increased interest expenses and operating costs related to the spin-off.
- Operating income decreased by 10% year-over-year, with margins compressed due to higher operating expenses and cost inflation, partially offset by pricing actions and cost productivity.
- The company ended the quarter with a healthy cash position of $1.9 billion, supported by $3.5 billion in available credit facilities.
- Remaining Performance Obligations (RPO) remained stable at $14.3 billion, indicating a solid backlog of future revenue.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q2 FY2023, GE HealthCare Technologies Inc. kept $0.09.
- Revenue$4.82B100.0%
- Cost of revenue−$2.88B59.7%
- Gross profit$1.94B40.3%
- Operating costs−$1.37B28.4%
- Operating income$570.0M11.8%
- Interest, other & tax−$152.0M3.2%
- Net income$418.0M8.7%
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2023filed July 25, 2023Financial Statements
Q2 FY2023 against Q2 FY2022
| Line item | Q2 FY2023Q2 FY2022 | Change |
|---|---|---|
| Revenue | $4.82B$4.48B | +7.4% |
| Gross Profit | $1.94B$1.80B | +8.0% |
| R&D Expenses | $298.00M$257.00M | +16.0% |
| SG&A Expenses | $1.07B$908.00M | +18.1% |
| Operating Expenses | $1.37B$1.17B | +17.6% |
| Operating Income | $570.00M$631.00M | −9.7% |
| Net Income | $418.00M$485.00M | −13.8% |
| EPS (Basic) | $0.92$1.07 | −14.0% |
| EPS (Diluted) | $0.91$1.07 | −15.0% |
| Shares Outstanding (Basic) | 455.00M454.00M | +0.2% |
| Shares Outstanding (Diluted) | 458.00M454.00M | +0.9% |
05—Questions
Frequently Asked Questions
What was the primary driver of revenue growth in the second quarter?
The primary driver of revenue growth was a combination of strong demand across all segments, improved supply chain fulfillment, and the impact of price increases. The Pharmaceutical Diagnostics (PDx) and Imaging segments, in particular, showed significant revenue increases.
What factors led to the decrease in net income despite revenue growth?
The decrease in net income was primarily due to higher interest expenses associated with recent debt issuances and the Term Loan Facility, as well as increased operating expenses related to the company's transition to a standalone entity and planned investments in R&D and commercial activities.
How is the company's financial position and liquidity?
GE HealthCare maintains a strong financial position, ending the quarter with $1.9 billion in cash and cash equivalents. The company also has access to $3.5 billion in revolving credit facilities, providing ample liquidity to meet its operational needs and financial commitments.
What is the outlook for future revenue based on the RPO?
The Remaining Performance Obligations (RPO) remained stable at $14.3 billion as of June 30, 2023. This indicates a substantial backlog of contracted revenue, with product-related RPO expected to be recognized within two years and service-related RPO within five years, providing visibility into future revenue streams.
06—Continue